P1. 13-33 Ex Vivo 2* 2* 2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer

S Ghosh; M Elkabets; K Kundu; L Roisman; D Levitas; A Porgador; N Peled

doi:10.1016/j.jtho.2018.08.890

P1. 13-33 Ex Vivo 2* 2* 2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer

S Ghosh, M Elkabets, K Kundu, L Roisman, D Levitas, A Porgador, N Peled

Research output: Contribution to journal › Meeting Abstract

Abstract

Lung cancer is one of the leading causes of cancer mortality worldwide. Despite of remarkable progress made in the lung cancer therapy, an unmet need is there in tailoring the appropriate patient specific therapy due to a variety of treatment options. Our aim was to develop a high-throughput drug screening method of tumor ex-vivo analysis (TEVA) which can predict patient-specific drug response and thus can be used for personalized cancer treatment.

Original language	English
Pages (from-to)	S595
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	10
DOIs	https://doi.org/10.1016/j.jtho.2018.08.890
State	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jtho.2018.08.890

Cite this

@article{7e884983f3ea4b13892a922a2d19470d,

title = "P1. 13-33 Ex Vivo 2* 2* 2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer",

abstract = "Lung cancer is one of the leading causes of cancer mortality worldwide. Despite of remarkable progress made in the lung cancer therapy, an unmet need is there in tailoring the appropriate patient specific therapy due to a variety of treatment options. Our aim was to develop a high-throughput drug screening method of tumor ex-vivo analysis (TEVA) which can predict patient-specific drug response and thus can be used for personalized cancer treatment.",

author = "S Ghosh and M Elkabets and K Kundu and L Roisman and D Levitas and A Porgador and N Peled",

year = "2018",

doi = "10.1016/j.jtho.2018.08.890",

language = "English",

volume = "13",

pages = "S595",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - P1. 13-33 Ex Vivo 2* 2* 2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer

AU - Ghosh, S

AU - Elkabets, M

AU - Kundu, K

AU - Roisman, L

AU - Levitas, D

AU - Porgador, A

AU - Peled, N

PY - 2018

Y1 - 2018

N2 - Lung cancer is one of the leading causes of cancer mortality worldwide. Despite of remarkable progress made in the lung cancer therapy, an unmet need is there in tailoring the appropriate patient specific therapy due to a variety of treatment options. Our aim was to develop a high-throughput drug screening method of tumor ex-vivo analysis (TEVA) which can predict patient-specific drug response and thus can be used for personalized cancer treatment.

AB - Lung cancer is one of the leading causes of cancer mortality worldwide. Despite of remarkable progress made in the lung cancer therapy, an unmet need is there in tailoring the appropriate patient specific therapy due to a variety of treatment options. Our aim was to develop a high-throughput drug screening method of tumor ex-vivo analysis (TEVA) which can predict patient-specific drug response and thus can be used for personalized cancer treatment.

U2 - 10.1016/j.jtho.2018.08.890

DO - 10.1016/j.jtho.2018.08.890

M3 - Meeting Abstract

SN - 1556-0864

VL - 13

SP - S595

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 10

ER -

P1. 13-33 Ex Vivo 2* 2* 2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this